Important Safety Information On Crysvita (burosumab) And The Risk Of Severe Hypercalcemia In Patients With Tertiary Hyperparathyroidism

CRYSVITA (burosumab) is being recalled across Canada because it can cause severe hypercalcemia (dangerously high calcium levels in the blood) in patients with tertiary hyperparathyroidism. This newly identified safety risk affects patients taking this medication who have this specific condition. The recall applies to all CRYSVITA distributed in Canada.

Product

CRYSVITA (burosumab)

Reason

New safety information - Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2025-08-25

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/af26062d-a5bd-43f4-bc8e-1c23f2692fa9